BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16104667)

  • 1. First-trimester screening for chromosomal abnormalities.
    Nicolaides KH
    Semin Perinatol; 2005 Aug; 29(4):190-4. PubMed ID: 16104667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
    Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
    Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
    Spencer K; Cowans NJ; Avgidou K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach to calculating the risk of chromosomal abnormalities with first-trimester screening data.
    Merz E; Thode C; Alkier A; Eiben B; Hackelöer BJ; Hansmann M; Huesgen G; Kozlowski P; Pruggmaier M; Wellek S
    Ultraschall Med; 2008 Dec; 29(6):639-45. PubMed ID: 19085755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
    Krantz D; Goetzl L; Simpson JL; Thom E; Zachary J; Hallahan TW; Silver R; Pergament E; Platt LD; Filkins K; Johnson A; Mahoney M; Hogge WA; Wilson RD; Mohide P; Hershey D; Wapner R;
    Am J Obstet Gynecol; 2004 Oct; 191(4):1452-8. PubMed ID: 15507982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
    Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fetal chromosomal abnormalities: antenatal screening and diagnosis.
    Anderson CL; Brown CE
    Am Fam Physician; 2009 Jan; 79(2):117-23. PubMed ID: 19178062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
    Maiz N; Valencia C; Emmanuel EE; Staboulidou I; Nicolaides KH
    Obstet Gynecol; 2008 Sep; 112(3):598-605. PubMed ID: 18757658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prenatal diagnosis in the first trimester, whom and how?].
    Hernández-Andrade E; Guzmán Huerta M; García Cavazos R; Ahued-Ahued JR
    Ginecol Obstet Mex; 2002 Dec; 70():607-12. PubMed ID: 12661334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of ductus venosus Doppler flow in the diagnosis of chromosomal abnormalities during the first trimester of pregnancy.
    Florjański J; Fuchs T; Zimmer M; Homola W; Pomorski M; Blok D
    Adv Clin Exp Med; 2013; 22(3):395-401. PubMed ID: 23828681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
    Spencer K; Cowans NJ; Molina F; Kagan KO; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Feb; 31(2):147-52. PubMed ID: 17992705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of assessment of trisomy 21--precise risk evaluation in the first trimester of pregnancy].
    Eiben B; Hammans W; Keuter S; Goebel R; Louwen F; Epplen J
    Z Geburtshilfe Neonatol; 2001; 205(3):94-8. PubMed ID: 11474996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced first trimester screening (AFS): an improved test strategy for the individual risk assessment of fetal aneuploidies and malformations.
    Schmidt P; Rom J; Maul H; Vaske B; Hillemanns P; Scharf A
    Arch Gynecol Obstet; 2007 Aug; 276(2):159-66. PubMed ID: 17342500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-trimester screening for trisomy 21 in twin pregnancy: does the addition of biochemistry make an improvement?
    Goncé A; Borrell A; Fortuny A; Casals E; Martínez MA; Mercadé I; Cararach V; Vanrell JA
    Prenat Diagn; 2005 Dec; 25(12):1156-61. PubMed ID: 16231401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.